Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MMpredict

Financiado

Cerrado

Validation of a personalised medicine tool for Multiple Myeloma that predicts tr...

Validation of a personalised medicine tool for Multiple Myeloma that predicts treatment effectiveness in patients The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients. MM is the second most common form of blood can... ver más

31/10/2020

ERASMUS MC

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-10-31

FTIPilot-1-2015: Fast Track to Innovation Pilot

I+D

Cerrada hace 9 años

0% 79% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

ERASMUS MC

419.69K€ | Lider

GESTOR ONLINE DE PRODUCTOS F...

UNITO

387.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PERSMEDOMICS Bioinformatics and Integrative Genomics for a Novel Personal... 100K€ Cerrado

NovaTests The first predictive test for radio sensitivity. A step towa... 71K€ Cerrado

PrECISE PERSONALIZED ENGINE FOR CANCER INTEGRATIVE STUDY AND EVALUAT... 6M€ Cerrado

PredAlgoBC Machine learning prediction for breast cancer therapy 185K€ Cerrado

EPI-FEM-CARE EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE 8M€ Cerrado

CANCER-ID Cancer treatment and monitoring through identification of ci... 21M€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2016-10-30
Fecha Fin: 2020-10-31

Líder del proyecto

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients. MM is the second most common form of blood cancer contributing to 15% of all blood cancers and ~1,5% and 2% of all cancer deaths annually in the EU and US, respectively. Patients show a large variability in treatment response and side effects due to tumour heterogeneity and the patient’s intrinsic characteristics. Therefore, not every treatment will be suitable for each patient, and treatment strategies are often based on trial-and-error. The availability of multiple (>20) treatment options complicates treatment decision-making even more. With the current development of many more promising treatments, there is an urgent unmet clinical need for a diagnostic assay that supports personalised cancer treatment in order to improve patient health outcomes, prevent side effects and reduce healthcare costs. SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test’s clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling. An addendum for new intended use will be filed to the current in vitro diagnostic (IVD) registration, while renaming the test to MMpredictor. The project will also focus on positioning the test as a cost-effective IVD test for personalised medicine, that will increase health outcome and quality of life of patients and reduce healthcare costs. The consortium consists of a life science SME specialised in molecular diagnostics, clinical centres with world renowned KOLs, a leading health economic institute, and a European MM patient advocacy organisation combining all the required complementary expertise to successfully bring the MMpredictor to market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores